is an activity-dependent and persistent increase in synaptic transmission. Currently available techniques to measure LTP are time-intensive and require highly specialized expertise and equipment, and thus are not well suited for screening of multiple candidate treatments, even in animal models. To expand and facilitate the analysis of LTP, here we use a flow cytometry-based method to track chemically induced LTP by detecting surface AMPA receptors in isolated synaptosomes: fluorescence analysis of single-synapse long-term potentiation (FASS-LTP). First, we demonstrate that FASS-LTP is simple, sensitive, and models electrically induced LTP recorded in intact circuitries. Second, we conducted FASS-LTP analysis in two well-characterized Alzheimer's disease (AD) mouse models (3xTg and Tg2576) and, importantly, in cryopreserved human AD brain samples. By profiling hundreds of synaptosomes, our data provide the first direct evidence to support the idea that synapses from AD brain are intrinsically defective in LTP. Third, we used FASS-LTP for drug evaluation in human synaptosomes. Testing a panel of modulators of cAMP and cGMP signaling pathways, FASS-LTP identified vardenafil and Bay-73-6691 (phosphodiesterase-5 and -9 inhibitors, respectively) as potent enhancers of LTP in synaptosomes from AD cases. These results indicate that our approach could provide the basis for protocols to study LTP in both healthy and diseased human brains, a previously unattainable goal.
Introduction
Learning and memory problems are increasingly prevalent with age, ranging from complaints in mild episodic memory to more severe and widespread cognitive dysfunction with Alzheimer's disease (AD) and other neurodegenerative diseases (Yankner et al., 2008; Negash et al., 2011) . It is generally believed that memory problems with age and AD arise from synaptic dysfunction and declines in synaptic plasticity, particularly in the hippocampus (Selkoe, 2002; Morrison and Baxter, 2012) . One of the most widely used models for studying molecular mechanisms of hippocampal synaptic plasticity is long-term potentiation (LTP), a rapid and remarkably persistent increase in synaptic transmission elicited by brief patterns of afferent activity (Bliss and Collingridge, 1993) . A growing body of experimental data supports that LTP is causally linked to synaptic processes underlying memory (Morris et al., 1986; Roman et al., 1987; Whitlock et al., 2006; ethyl ester (calcein AM; ultrapure grade, Affymetrix, eBioscience, #65-0853-39) . Chemicals were from Sigma-Aldrich: 4-aminopyridine (4-AP), AP5, glycine, DMSO, KN-62, and anisomycin; from R&D Systems: TrkB-Fc.
FASS-LTP. (1) Synaptosome isolation:
Fresh crude synaptosome P2 fractions were obtained from whole mouse hippocampus using our longstanding protocol (Sandoval et al., 1978) . All the steps for synaptosome P2 fraction isolation were performed at 4°C; sucrose buffer, grinder, pestle, and Microfuge tubes were all precooled on ice. Hippocampi were rapidly dissected form a single mouse and homogenized in 320 mM sucrose (1.5 ml) containing HEPES [10 mM] and protease/phosphatase inhibitors mixture (Pierce), pH 7.4. Homogenization consisted of 6 -8 manual strokes in a Glass-Teflon grinder, clearance (between plunger and glass): 0.15-0.25 mm. Plunger was gently rotated during strokes while the grinder was kept on ice. The homogenate was centrifuged at 1200 ϫ g for 10 min. Supernatant (S1, containing mitochondria and synaptosomes) was transferred into two clean Microfuge tubes and centrifuged at 12,000 ϫ g for 20 min. Supernatants (S2) were carefully removed using a plastic tip and vacuum. Pellets (P2, corresponding to the crude synaptosome fraction) were resuspended by gently pipetting up and down (10 -20 times) in 1.5 ml of extracellular (tube 1) or cLTP (tube 2) solutions. Extracellular solution contains the following (in mM): 120 NaCl, 3 KCl, 2 CaCl 2 , 2 MgCl 2 , 15 glucose, 15 HEPES, pH 7.4; whereas cLTP solution is Mg 2ϩ -free and contains the following (in mM): 125 NaCl, 2 CaCl 2 , 5 KCl, 10 HEPES, 30 glucose, pH 7.4 (Park et al., 2006) . Synaptosome P2 fractions were filtered with a 40 m pore cell strainer (BD Biosciences) and incubated in a cell culture dish (30 mm) with agitation at room temperature for 10 -15 min for recovery. Similarly, cryopreserved (Ϫ80°C) P2 fraction from human brain was rapidly thawed in a warm bath, filtered (40 m pore) and incubated in a cell culture dish (30 mm) with agitation at room temperature for 10 min. A P2 fraction aliquot was used to determine protein concentration (BCA assay using BSA as a standard). To prevent synaptosome damage, Finntip pipette tips (Thermo) were used to handle human, mouse, and rat synaptosome samples.
(2) Stimulation: After recovery, 180 l synaptosomes (50 -200 g protein, BCA assay) maintained in cLTP solution were transferred to cytometry tubes. As control, an equal volume (180 l) of synaptosome maintained in external solution was also transferred to a cytometry tube. Synaptosomes in external solution were used to determine basal levels of potentiated synaptosomes (see below). All cytometry tubes were prewarmed in a 37°C bath (5 min) before stimulation. External, glycine, and KCl solutions were also prewarmed at 37°C. Next, 20 l of external solution was added to control synaptosomes (in external solution), whereas 20 l of glycine ([5 mM] in cLTP solution freshly supplemented with 0.01 mM strychnine and 0.2 mM bicuculline methiodide) was added to synaptosomes in cLTP solution (final [glycine] ϭ 0.01 M) (Chen et al., 2011) . Glycine was incubated for 15 min to prime synaptic NMDAR. After glycine treatment, synaptosomes were depolarized with 100 l of a ͫhighͬ KCl solution consisting of the following (in mM): 50 NaCl, 2 CaCl 2 , 100 KCl, 10 HEPES, 30 glucose, 0.5 glycine 0.001 strychnine, 0.02 bicuculline methiodide, pH 7.4 (final [KCl] ϭ 37 mM), and incubated for 30 min; 100 l of external solution was added to control synaptosomes. KCl is used to depolarize and induce the release of endogenous glutamate from presynaptic terminals (Bradford, 1970; Nicholls and Sihra, 1986) . Because the presynaptic active zone is adjacent to postsynaptic density (PSD), this protocol activates synaptic NMDARs preferentially. After KCl incubation, stimulation was stopped by sequential addition of 0.5 ml of ice-cold 0.1 mM EDTA-PBS, pH 7.4, and 4 ml of ice-cold blocking buffer (5% FBS in PBS). Tubes were chilled on ice and immediately centrifuged at 2500 ϫ g for 6 min at 4°C (9000 rpm, Sorvall RT6000B). After centrifugation, the pellet was resuspended by gentle finger agitation (no vortex) and kept on ice. To test NMDAR dependence (see Fig. 4C ), P2 pellets were resuspended in external or cLTP solutions containing AP5 (100 M) or DMSO (control), maintained at room temperature for 15 min, and prewarmed at 37°C (5 min) before stimulation with 20 l of 5 mM glycine (0.01 mM strychnine, 0.2 mM bicuculline methiodide). Glycine solution also contained either 100 M AP5 or DMSO. To test different KCl concentrations (see Fig. 4B ), after glycine incubation (15 min), synaptosomes were treated with 50, 100, and 200 l of ͫhighͬ KCl solution. Final concentrations of each ion were obtained, and the corresponding membrane potentials (V m ) were calculated based on Goldman-Hodgkin-Katz equation (below), using the calculator at http:// www.physiologyweb.com/calculators/ghk_equation_calculator.html. V m values were Ϫ49, Ϫ41, and Ϫ31 mV using 50, 100, and 200 l ͫhighͬ KCl solution, respectively, as follows:
(3) Immunolabeling: Primary antibody solution (400 l) was added to the resuspended pellet and incubated for 30 min on ice with agitation. Primary antibody solution contained rabbit anti-GluA1 (Molnár et al., 1993; Richmond et al., 1996) (ABN241) and mouse anti-Nrx1␤ (University of California-Davis/National Institutes of Health NeuroMab Facility, 75-216) antibodies, both at 2.5 g/ml in blocking buffer (5% FBS in PBS). Similar results are obtained with rabbit anti-GluA1 (Cell Signaling Technology, #13185; 1:400). After incubation, synaptosomes were washed (2 times) with 4 ml of ice-cold blocking buffer and centrifuged (2500 ϫ g/5 min/4°C). Supernatant was discarded and pellet gently resuspended as previously described. Secondary antibody solution (400 l) was added to each tube and incubated for 30 min on ice with agitation and protected from light. After incubation, synaptosomes were washed as previously described. Secondary antibody solution contained anti-rabbit-Alexa-488 and anti-mouse-Alexa 647 antibodies (Invitrogen), both at 2.5 l/ml. Endogenous/nonspecific background fluorescence for each marker was determined using secondary antibody staining only in a tube containing synaptosomes maintained in external solution (37°C, 45 min); no differences in background fluorescence were found when comparing synaptosomes in external solution (basal state) or following cLTP stimulation. After the last wash, the pellet was resuspended as previously described and 400 l of 2% PFA in PBS was added to each tube. Samples were protected from light, maintained at 4°C, and run on a flow cytometer within 48 h.
(4) Flow cytometry: Samples were acquired using BD FACSCalibur flow cytometer (BD Biosciences) equipped with argon 488 nm and helium-neon 635 nm lasers. Relative size and granularity were determined by forward scatter (FSC) and side scatter (SSC) properties. FSC, SSC, and fluorescence (FL1 [530 Ϯ 15 nm] and FL4 [650 Ϯ 25 nm]) signals were collected using log amplification. FSC-SSC plots were used to select particles matching the size of synaptosomes (0.75-3.0 m) using calibrated beads (Polysciences) (see Fig. 1 A, B) , as previously described (Fein et al., 2008) . Identical FSC settings were used for acquiring data on bead standards and samples. Small fragments and debris were excluded by establishing an FSC-H threshold (gain ϭ 325). Settings for fluorescence amplification on FL1 and FL4 photomultiplier tube detectors were based on the emission detected on size-based gated particles. Alexa-488 and Alexa-647 fluorochromes were detected by the FL1 and FL4 detectors, respectively. Synaptosome integrity was assessed with calcein AM using the FL1 detector (to detect the fluorescent molecule calcein). A total of 10,000 size-gated particles were collected and analyzed for each sample; event rate: ϳ500/s. Analysis was performed using the CellQuest Pro software (BD Biosciences). Gates are set based on standard immunostaining protocols for flow cytometry (Baumgarth and Roederer, 2000; Hulspas et al., 2009; Menon et al., 2014) . Briefly, we use staining controls to discriminate background fluorescence due to both sample itself and unspecific binding of fluorescence-labeled antibodies. These controls are synaptosomes incubated only with secondary antibodies (no primary antibodies). The presence of doublets and multiplets (clumps) was assessed by FSC-H versus FSC-A plots (Doublet discrimination) using a BD FACSAria Fusion cytometer and Flow Jo software (LLC). Briefly, the amount of light scattered in the forward direction (FSC) is processed as a voltage pulse, which is defined by its area (A), height (H), and width (W). Disproportions between height, width, and area are used to identify doublets and clumps. P2 fraction-derived events exhibited a single-particle profile in both basal and cLTP conditions, as assessed in FSC-H versus FSC-A bivariate plot (data not shown).
Intracellular immunolabeling. This was performed using 50 -100 g P2 fractions ([protein] by BCA assay). Samples were fixed with 4% PFA for 20 min at room temperature, chilled on ice, and permeabilized by adding ice-cold 100% methanol slowly, while gently vortexing, to a final concentration of 90% methanol and incubating 15 min on ice. Samples were washed with ice-cold PBS, blocked with 200 l of Blocking/Perm buffer (5% FBS, 0.2% Tween 20 in PBS) for 10 min and stained by adding 200 l of primary antibody (RT, 30 min on agitation). Samples were washed (2 times) with ice-cold Blocking/Perm buffer, and pellets were resuspended in 400 l 2% PFA. Most primary antibodies were at 2.5 g/ml in 400 l blocking Blocking/Perm buffer; synapsin-I antibody was at 1 g/ml. Endogenous/nonspecific background fluorescence was determined by using secondary-conjugated antibodies.
Electrophysiology. Acute hippocampal slices were prepared from 8-week-old male Sprague Dawley rats (Harlan Laboratories) for extracellular field recordings. Rats were decapitated and the brain quickly submerged in ice-cold, oxygenated, high magnesium ACSF containing the following (in mM): 124 NaCl, 3 KCl, 1.25 KH 2 PO 4 , 5 MgSO 4 , 26 NaHC0 3 , and 10 dextrose. A McIlwain tissue chopper was used to prepare 400-m-thick slices from the middle third of the hippocampal septotemporal axis. Slices were then transferred to an interface recording chamber maintained at 31 Ϯ 1°C (95% O 2 /5% CO 2 ) and continuously perfused with preheated oxygenated ACSF containing the following (in mM): 124 NaCl, 3 KCl, 1.25 KH 2 PO 4 , 1.5 MgSO 4 , 26 NaHCO 3 , 2.5 CaCl 2 , and 10 dextrose at a rate of 60 -70 ml/h. Recordings began Ն1.5 h after transfer to the chamber. Field EPSPs (fEPSPs) were evoked in CA1a and CA1c stratum radiatum using a bipolar stimulating electrode (twisted nichrome wire, 65 m) and recorded in CA1b stratum radiatum using a glass electrode (2 M NaCl, 2-3 M⍀). Before theta burst stimulation (TBS, 10 bursts of 4 pulses at 100 Hz, 200 ms between bursts) test pulses at 0.05 Hz were delivered at a baseline stimulation intensity that yielded response amplitudes ϳ50% of the maximum spike-free fEPSP. For induction of LTP, a high-intensity TBS protocol was used consisting of four trains separated by 15 s as follows: one train was delivered at both polarities of each stimulating electrode. Stimulation intensity was increased to near-spike threshold only during TBS and then returned to baseline Size-gated events exhibited a single-particle profile, as determined by Doublet discrimination analysis (see Materials and Methods). C, Detection of synaptic, nuclear, and viability markers in size-gated particles from the P2 fraction. Boxplots percentiles: box, 25th-75th; whiskers, 10th-90th. Synaptic markers: postsynaptic density protein 95 (PSD95, n ϭ 17), synaptophysin (SYP, n ϭ 7), synapsin-I (n ϭ 4), AMPA glutamate receptor subunit 2 (GluA2, n ϭ 4), tropomyosin receptor kinase B (TrkB, n ϭ 4), vesicular glutamate transporter 1 (VGluT1, n ϭ 4), NMDA glutamate receptor subunit 2B (GluN2B, n ϭ 4); nuclear marker: histone-H3 (n ϭ 5); viability marker: calcein (n ϭ 4); n ϭ number of independent experiments (number of mice). D, Representative histograms of data presented in C. Thresholds for endogenous/nonspecific fluorescence for each marker were set using a proper secondary antibody (dotted line) or unstained samples (control for calcein staining). PSD95, SYP, synapsin-I, VGluT1, and histone-H3 were detected by intracellular staining, whereas GluA2, TrkB, and GluN2B were detected following a surface (extracellular) staining protocol. E, In size-gated particles, representative two-parameter density plots for SYP-PSD95 (intracellular) (using a rabbit anti-PSD95 antibody to prevent cross-reactivity), synapsin-I-PSD95 (intracellular) , GluA1-PSD95 (intracellular) (using a mouse anti-PSD95 antibody to prevent cross-reactivity), and GluA2-GluN2B (extracellular) . Numbers indicate percentage of events at the top right quadrant, which contains double-positive particles. Top, Representative plot shows how thresholds for endogenous/nonspecific fluorescence for each marker are set by staining with secondary antibodies only (2°abs for fluorescence-1 and -4 channels, FL1 and FL4, respectively). F, The 20 g of lysates from total homogenate, nuclear (Nuc, P1), and crude synaptosomal (Syn, P2) fractions was resolved by SDS-PAGE and immunoblotted. Compared with the nuclear fraction, the synaptosomal fraction contained higher levels of VGluT1 (ϳ52 kDa), (Figure legend continues.) intensity. In all instances, initial slopes and amplitudes were measured from digitized fEPSPs (NACGather 2.0, Theta Burst). Slices were collected 30 -60 min after TBS for FASS-LTP preparation. CA1 area (ϳ0.4 mm 2 ) surrounding the recording electrode was punched out by using a biopsy punch sampler (size: 2.0 mm; Harris Uni-Cores, Electron Microscopy Sciences, #69036 -20) and a cutting mat (Electron Microscopy Sciences, #69037-23). P2 fraction isolation, GluA1 and Nrx1␤ immunolabeling, and flow cytometry analysis were performed immediately, as described above (see FASS-LTP immunolabeling). Biochemistry. Total homogenates, P1 and P2 fractions, were obtained from whole mouse hippocampus and lysed in RIPA buffer (RIPA/Nonidet P-40 buffer containing protease and phosphatase inhibitor mixtures [Pierce, Thermo Fisher Scientific]) by vortex 10 s at high speed. Protein concentration was determined by the BCA assay (Pierce, #23227). All samples were supplemented with Laemmli buffer, boiled (7 min), run on Criterion XT gels, and then transferred to PVDF membranes according to the manufacturer's instructions (Bio-Rad). Membranes were blocked in 5% BSA for 1 h and then probed with primary antibody (4°C, overnight). The membranes were washed (4 ϫ 10 min in TBS with 0.1% Tween 20, v/v) and probed with HRP-conjugated secondary antibody for 1 h. The membranes were washed and developed using Chemiluminescent Substrate (Pierce, #32106) or Luminata Crescendo Western HRP substrate (Millipore). Some blots were washed, stripped, and reprobed with antibodies to GAPDH or ␤-actin. Membranes were incubated in stripping buffer (Pierce, #46430) according to the manufacturer's instructions.
Synaptosome sorting and immunoprecipitation. Sorting experiments were performed on a BD FACSAria Fusion cytometer, using light scatter discrimination (FSC-H, SSC-H, and doublet discrimination). First, synaptosomes were identified by size using calibrated beads (0.75-3.0 m; see Fig. 1 A, B) , and 200,000 size-gated synaptosomes were sorted for each condition (basal vs cLTP). Sorted synaptosomes were collected in 250 l of RIPA buffer containing protease and phosphatase inhibitors. Immediately after synaptosome collection, the volume was adjusted to 500 l and immunoprecipitation was performed with a commercially available kit (Active Motif). Briefly, samples for each condition were incubated overnight with rotation at 4°C with a rabbit anti-GluA1 antibody (Cell Signaling Technology; #13185; 10 g) or with a rabbit anti-PSD95 (Abcam #ab18258, 10 g) antibody. As a negative control, a sample (basal condition) was incubated with a control rabbit IgG (Thermo, #02-6102, 10 g). After incubation, protein-G magnetic beads were added and incubated for 1 h with rotation at RT. Protein complexes were magnetically precipitated according to the manufacturer's instructions, lysed with Laemmli buffer (4ϫ), boiled (10 min), run on Criterion XT gels, and transferred to PVDF membranes. Antibodies used for blotting were as follows: rabbit anti-GluA1 (Cell Signaling Technology; 1:1000) and mouse anti-PSD95 (Millipore MAB1598; 1:1000). For stripping between first and second blotting, membranes were incubated in stripping buffer (Pierce, #46430) according to the manufacturer's instructions.
Statistical analyses. Sample sizes were chosen on the basis of preliminary experiments using synaptosomes (Prieto et al., 2015) and previous experience with in vitro LTP recordings in hippocampal slices (Rex et al., 2007) . ANOVA and two-tailed Student's t test (parametric tests) were used where assumptions of normality (Kolmogorov-Smirnov) and equal variance (Bartlett's test) were met, and were replaced by Kruskal-Wallis and Mann-Whitney test (nonparametric tests) where appropriate. For mean comparisons of three or more groups, one-way ANOVA was followed by post hoc Tukey's or Dunnett's (to compare each of a number of treatments with a single control test); whereas Kruskal-Wallis was followed by Dunn's post hoc test. Two-way ANOVAs were followed by Bonferroni's post hoc test. Welch's correction was used in unpaired data Student's t test analysis when samples had unequal variances. Statistical tests were performed using GraphPad Prism 5.0. Data are presented as mean Ϯ SEM. A p value Ͻ 0.05 was considered significant.
Results

FASS-LTP identifies potentiated synaptosomes
Previous studies have shown that synaptosomes can be identified by flow cytometry using size-calibrated beads (Wolf and Kapatos, 1989a, b; Fein et al., 2008; Postupna et al., 2014) , a strategy based on the analysis of the forward-scattered (FSC) light, which is proportional to the size of particles. We first evaluated whether flow cytometry could selectively and reliably identify synaptosomal particles from the crude P2 fraction, which can be rapidly obtained (ϳ30 min) and is enriched in synaptosomes (Sandoval et al., 1978) . Notably, in addition to canonical synaptosomes (presynaptic terminals with an adherent fragment of postsynaptic membrane), P2 fractions from rodents (Cotman et al., 1974; Rao and Steward, 1991; Bagni et al., 2000; Maurer et al., 2008; Corera et al., 2009; Nisticò et al., 2015) and humans (Hahn et al., 2009; Postupna et al., 2014) also contains "snowman-shaped" synaptosomes with a resealed postsynaptic element, which contains sparse membranous organelles identified by electron microscopy (Corera et al., 2009; Hahn et al., 2009 ) and cryo-electron tomography (Maurer et al., 2008) . In crude P2 fractions from mouse hippocampus, we gated a population of particles between 0.75 and 3.0 m using size-calibrated beads ( Fig. 1 A, B) . Consistent with the average size of synaptosomes (Jones and Bradford, 1971; Wilhelm et al., 2014) , we found that the subset of particles between 0.75 and 3.0 m is enriched in synaptosomes, as demonstrated by the high proportion of particles expressing extracellular and intracellular synaptic markers (e.g., PSD95) with no histone-H3 (nuclear) (Fig. 1C ,D); we refer to these particles as size-gated synaptosomes. Double-labeling indicated that most size-gated synaptosomes contain presynaptic and postsynaptic markers (e.g., synapsin-I ϩ PSD95 ϩ ϳ70%; Fig.  1E ), and that most GluA1 ϩ events coexpress PSD95 ( Fig. 1E ), indicating that AMPA receptors are detected in particles containing postsynaptic densities. By Western blot, we validated the synaptic enrichment of our preparation ( Fig. 1F ) and the specificity of antibodies used for immunostaining ( Fig. 1G ). We also demonstrated the viability of our preparation using calcein AM, a dye that evaluates cell membrane integrity and viability. Size-gated synaptosomes stained positive for calcein (Ͼ90%; Fig. 1C,D) . These data confirm that flow cytometry selectively and reliably identifies viable synaptosomal particles from the crude P2 fraction.
We envisioned that, in the size-gated synaptosome population, potentiated synapses could be detected by extracellular membrane surface labeling (without permeabilization) using antibodies specific for extracellular epitopes on GluA1 (Richmond et al., 1996) and neurexin-1␤ (Nrx1␤), a presynaptic adhesion molecule stabilized at the membrane surface by synaptic activity (Fu and Huang, 2010) . At excitatory synapses, Nrx1␤ promotes presynaptic differentiation and captures postsynaptic surface GluA1 via PSD95 (de Wit et al., 2009; Mondin et al., 2011) . Thus, GluA1 and Nrx1␤ double-labeling further allows us to focus on "snowman-shaped" synaptosomes that contain both presynaptic and postsynaptic elements. To induce cLTP, synaptosomes were primed with 500 M glycine (Chen et al., 2011 ) (15 min) followed by depolarization using 37 mM KCl (30 min) (Nicholls and Sihra, 1986), at 37°C. In parallel, to determine basal levels of GluA1 ϩ Nrx1␤ ϩ , a synaptosome sample was maintained in exter-4 (Figure legend continued.) GluA1 (ϳ100 kDa), and synaptophysin (ϳ38 kDa), but no detectable signal of the nuclear matrix protein p84 (ϳ84 kDa). GAPDH and ␤-actin were used as loading controls. G, Synaptosomal fractions were also tested for PSD95 (ϳ95 kDa), synapsin-I (syn-I, ϳ77 kDa), GluA2 (ϳ100 kDa; secondary band at ϳ70 kDa), GluN2B (ϳ166 kDa), TrkB (ϳ120 kDa; secondary band at ϳ90 kDA, which is likely a TrkB truncated form), and Nrx1␤ (ϳ50 kDa; secondary bands at ϳ41 and ϳ35 kDa, which are likely splice variants).
nal solution (37°C, 45 min) and treated with identical volumes of external solution instead of glycine or KCl.
After cLTP induction (45 min), we observed an increased proportion of GluA1 ϩ Nrx1␤ ϩ events over basal levels (246 Ϯ 21%, p ϭ0.0002 vs basal, n ϭ 8, unpaired Student's t test; Fig. 2A,B) , demonstrating that FASS-LTP detects activitydependent plasticity at the synaptosome surface. We consistently found that up to ϳ25% of the size-gated synaptosomes increase surface GluA1 levels after cLTP stimulation, thus indicating that a reliable fraction of particles (ϳ2500 of 10,000 acquired events) contains functional postsynaptic elements. Subpopulation analysis performed in GluA1-Nrx1␤ density plots revealed that GluA1 ϩ Nrx1␤ ϩ particles (top right quadrant) exhibit the highest mean fluorescence intensity for GluA1 (p ϭ0.0023; Fig. 2C ) and concentrate most Nrx1␤ ϩ particles (p ϭ0.0002; Fig. 2D ), supporting the idea that cLTP simultaneously orchestrates an upregulation of postsynaptic GluA1 levels while facilitating the expression of presynaptic Nrx1␤ at the synaptosomal surface. Notably, in both basal and cLTP conditions, GluA1 ϩ Nrx1␤ ϩ particles were found to exhibit the highest GluA1 surface levels (Fig. 2C) , thus indicating that our approach can identify potentiated synaptosomes even at low basal levels.
As FASS-LTP is based on surface synaptosome labeling, this method relies on synaptosome membrane integrity. To evaluate the effects of our cLTP protocol on membrane integrity, we determined whether calcein AM loaded before the incubation period (37°C) remains inside the synaptosomes at the end of the experiment (45 min). Synaptosomes were loaded with 20 nM calcein AM and either stimulated with our cLTP protocol or maintained and treated with equivalent volumes of external solution (basal state). After 45 min, we found high levels of calcein ϩ events on both basal and cLTP conditions, relative to unloaded synaptosomes (% calcein ϩ : basal ϭ 93.4 unpaired t test, n ϭ 7, 3-to 4-month-old mice). To further assess membrane integrity, we tested antibody penetration in synaptosomes. After 45 min of cLTP or control treatment (external solution), synaptosomes were incubated (no permeabilization) with an antibody against the cytosolic kinases ERK1/2 (extracellular signalregulated kinases-1 and -2), two MAP kinases that play a key role in synaptic plasticity (Thomas and Huganir, 2004) . No labeling was found in either basal or cLTP conditions ( Fig. 2E,F) . In contrast, a positive intracellular signal for ERK1/2 was observed when synaptosomes were permeabilized ( Fig. 2E,F) . Overall, these data indicate that synaptosomal membrane integrity is preserved in our experimental conditions, thus preventing false-positive surface labeling due to antibody internalization.
FASS-LTP models electrically induced LTP recorded in intact circuitries
To demonstrate the physiological relevance and specificity of our cLTP synaptic potentiation paradigm, we used flow cytometry to evaluate whether parallel changes in GluA1 ϩ Nrx1␤ ϩ surface expression are present in synaptosomes prepared from mature hippocampal slices (8-week-old rat) that had undergone electrophysiological induction of LTP. We induced LTP at CA1 by naturalistic theta burst stimulation (TBS) at Schafer collaterals from CA3 hippocampus. After confirming that stable LTP was established following TBS (Fig.  3A) , the CA1 area was punched out (Fig. 3B ) and immediately processed for synaptosomal isolation and flow cytometry analysis. We found that TBS of hippocampal slices increased the number of GluA1 ϩ Nrx1␤ ϩ synapses present in isolated synaptosomes (p Ͻ 0.019; Fig. 3C,D) , paralleling our findings in cLTP-stimulated synaptosomes from mice ( Fig. 2A,B ) and rats (143 Ϯ 15% over basal, p ϭ0.029, Mann-Whitney test, n ϭ 4). These data demonstrate that TBS-LTP and cLTP converge on a common molecular readout, namely, increased surface coexpression of GluA1 and Nrx1␤. Further analysis of the extent to which FASS-LTP reproduces the essential features of electrically induced LTP revealed important parallels. Time course analysis demonstrated that the early (15 min) increase in the proportion of GluA1 ϩ Nrx1␤ ϩ events after cLTP stimulation is sustained up to 75 min (Fig. 4A) , resembling the long-lasting increase in EPSPs that defines LTP. In addition, we found that our cLTP protocol depends on priming of NMDAR by glycine and on synaptosome KCl depolarization ( Fig. 4A) , which favors glutamate release and voltage-dependent postsynaptic signaling. In glycine-primed synaptosomes, chemically induced depolarization at Ϫ49, Ϫ41, and Ϫ31 mV using increasing concentrations of KCl (24, 37, and 52 mM) revealed that 37 mM (Ϫ41 mV; p Ͻ 0.01) and 52 mM (Ϫ31 mV; p Ͻ 0.05) but not 24 mM KCl (Ϫ49 mV) induce cLTP in synaptosomes (Fig. 4B) . In contrast, we found a weak cLTP response in glycineprimed synaptosomes depolarized (30 min) by 2.5 mM 4-AP (equimolar substitution of NaCl by 4-AP in the cLTP solution; percentage GluA1 ϩ Nrx1␤ ϩ basal vs 4-AP ϭ 100.0 Ϯ 14.6 vs 132.2 Ϯ 27.3; p ϭ 0.33, unpaired t test, n ϭ 5, 3-to 4-month-old mice). Importantly, the NMDAR antagonist AP5 blocks the cLTP-driven increase in GluA1 ϩ Nrx1␤ ϩ synaptosome levels (Fig. 4C ), paralleling the NMDAR dependence of hippocampal LTP previously established by electrophysiological recordings in vivo (Morris et al., 1986) and in vitro using brain slices (Collingridge et al., 1983) . In addition, we found that cLTP in synaptosomes is blocked by inhibiting Ca 2ϩ /calmodulin-kinase II (CaMKII), an enzyme that increases AMPAR conductance via GluA1 phosphorylation (Derkach et al., 1999) (Fig. 4D ). Similarly, either K252a (protein tyrosine kinase inhibitor) or anisomycin (protein synthesis inhibitor) prevented the increase in GluA1 ϩ Nrx1␤ ϩ levels following cLTP stimulation (Fig. 4D) . In further parallel, application of TrkB-Fc fusion protein, the BDNF scavenger that prevents electrically induced LTP, also blocked synaptosomal cLTP (Fig. 4D ). Finally, because an important pathway for enduring LTP depends on PKA activation (Nguyen and Woo, 2003) , we tested the effect of modulators of PKA activity on synaptosomal cLTP. Either H-89 (PKA inhibitor) or SQ22536 (adenylyl cyclase [AC] inhibitor) blocked cLTP (Fig.  4D ). Overall, these findings are consistent with the essential roles of CaMKII (Malinow et al., 1989; Silva et al., 1992) , tyrosine kinases (O'Dell et al., 1991) , protein synthesis (Fonseca et al., 2006) , PKA (Nguyen and Woo, 2003) , and BDNF signaling (Rex et al., 2007) in LTP, demonstrating that FASS-LTP reproduces the defining characteristics of the long-lasting EPSP enhancement in hippocampus seen after electrical stimulation (i.e., LTP).
GluA1-containing AMPAR are located and concentrated at dendritic spines. However, because extracellular GluA1-labeling detects GluA1 at both synaptic and extrasynaptic synaptosomal surface, we evaluated whether cLTP increases GluA1 levels at the PSD by assessing the physical interaction of GluA1 with PSD95. After cLTP stimulation, GluA1 was immunoprecipitated from 200,000 synaptosomes sorted by size using calibrated beads (0.75-3.0 m) ( Fig. 5A ). Compared with nonstimulated synaptosomes, cLTP increased GluA1-PSD95 interaction levels, as quantified by PSD95 immunoblotting (Fig. 5 B, D) . We further tested GluA1-PSD95 coimmunoprecipitation by PSD95 immunoprecipitation (IP) and GluA1 immunoblotting. Following PSD95 IP, we found increased GluA1 levels in cLTP-stimulated synaptosomes compared with controls maintained in external solution (Fig. 5C,E) . As PSD95 is a major scaffolding protein of the PSD, these experiments demonstrate that cLTP increases GluA1 levels at the PSD in synaptosomes. FASS-LTP revealed that, although comparable GluA1 ϩ Nrx1␤ ϩ levels after chemical stimulation were observed in young non-tg and 3xTg mice, cLTP was absent in aged 3xTg mice (p Ͻ 0.001, young vs aged 3xTg; Fig. 6A,B ). This profile is consistent with electrophysiological recordings in 3xTg showing intact LTP at 3-4 months but significant deficits in 6-to 7-month-old mice (Oddo et al., 2003) . In addition, FASS-LTP detected an age-related impairment of cLTP in non-tg mice (p Ͻ 0.01, young vs aged non-Tg; Fig. 6A,B) , consistent with the decline in hippocampal LTP observed in mice at mid-life (ϳ15 months) (Bach et al., 1999) . However, cLTP was significantly lower in aged 3xTg compared with aged non-tg mice (p Ͻ 0.05, 3xTg vs non-tg; Fig.  6A,B) , supporting the idea that transgenedriven expression of AD pathology further reduces synaptic plasticity beyond the effects of aging alone (Oddo et al., 2003) . We also used FASS-LTP to assess synaptic plasticity in the Tg2576 model, one of the best characterized mouse models of AD (Hsiao et al., 1996; Jacobsen et al., 2006 Fig. 6C,D) . Thus, through using two wellcharacterized AD mouse models, we found strong support for the idea that AD-driven mechanisms impair LTP directly at the synapse. ), direct evidence of LTP deficits in human AD brain has been elusive, primarily due to methodological limitations. To address this fundamental question, we used FASS-LTP on synaptosomal fractions from cryopreserved human cortex. We found that, although cLTP stimulation induced an increase in GluA1 ϩ Nrx1␤ ϩ levels in synaptosomes from human control tissue (p Ͻ 0.05), there was no detectable change in GluA1 ϩ Nrx1␤ ϩ levels in AD tissue (Fig. 6E,F Fig. 6G,H) . Overall, these data provide the first direct evidence to support the idea that synapses from the AD-diseased brain are intrinsically defective in LTP. Based on the unique capacity of FASS-LTP to monitor synaptic plasticity in human brain tissue, a widely useful application of this method would be drug screening, performed directly in human brain tissue, to identify candidates that restore LTP to defective synapses in AD. Indeed, the need for better identification of candidate drugs for treatment of AD is underscored by the high failure rate of AD drug clinical trials (99.6% failures on Ͼ400 trials) (Cummings et al., 2014) despite the preclinical evidence of drug effectiveness demonstrated in animal tissue. We next use FASS-LTP to screen for drugs that restore LTP in AD, testing multiple agents in parallel directly in human AD tissue (40 synaptosomal samples obtained from 100 -200 mg tissue).
LTP is impaired in synapses from human AD brain
Enhancement of cGMP signaling rescues LTP in the AD-diseased brain
Pharmacological enhancement of LTP has been widely focused on approaches that augment the PKA/CREB pathway, a signaling cascade that depends on cAMP production by AC (Nguyen and Woo, 2003) . Because cAMP levels are reduced by phosphodiesterases (PDEs) (a family of enzymes that hydrolyze cyclic nucleotides), PDE inhibitors (PDEi) (which prevent the chemical breakdown of cAMP and cGMP) represent a potential treatment strategy for enhancing LTP and preventing memory decline . The effectiveness of PDEi to enhance LTP and/or memory has been demonstrated in animal models with inhibition of PDE2 (Boess et al., 2004) , PDE4 (Gong et al., 2004; Rutten et al., 2008) , PDE5 (Prickaerts et al., 2002; Puzzo et al., 2009; Cuadrado-Tejedor et al., 2011; Reneerkens et al., 2012; Akkerman et al., 2015) , and PDE9 (Kroker et al., 2012; Kroker et al., 2014) . Whether PDE inhibition similarly enhances LTP in human tissue is unknown.
We used FASS-LTP in human synaptosomes from control and AD cases to interrogate in parallel the effectiveness of 7 selective PDE inhibitors to enhance LTP, specifically inhibiting PDE2 (Bay-60 -7550, 0.5 M), PDE4 (rolipram, 30 M), PDE5 (vardenafil, 0.1 M; sildenafil, 0.5 M; tadalafil, 0.2 M), and PDE9 (Bay-73-6691, 10 M). In parallel, we tested forskolin (adenylyl cyclase activator, AC activ ) and cinaciguat (guanylyl cyclase activator, GC activ ), as well as functionally relevant combinations of PDEi with AC activ or GC activ . Thus, a total of 18 treatments were simultaneously tested on basal conditions (external solution) and after cLTP (i.e., ϳ40 human synaptosome samples) ( Fig. 7A-C) . We found that, in synaptosomes from AD cases, GluA1 ϩ Nrx1␤ ϩ levels were not increased after cLTP stimulation, even in synaptosomes treated with PDEi alone (in the absence of AC activ or GC activ ) ( Fig. 7 A, B) . In contrast, cLTP was rescued in synaptosomes from AD cases by the combination of GC activ with PDE5 inhibition (vardenafil) or PDE9 inhibition (Bay-73-6691) ( p Ͻ 0.05; Fig. 7 A, B) , suggesting that synaptic plasticity in the human AD brain may be rescued by enhancing cGMP signaling. In synaptosomes from control human cases, GluA1 ϩ Nrx1␤ ϩ levels were increased in basal conditions after cLTP stimulation ( Immediately, 200,000 size-gated synaptosomes (Fig. 1A, B) were sorted using a FACSAria Fusion sorter (sample and sort collection tubes were maintained at 4°C during sorting). Sorted synaptosomes were immediately lysed and immunoprecipitated using (B) rabbit anti-GluA1 (N-terminal) and (C) rabbit anti-PSD95 (amino acids 50 -150) antibodies. As a negative control, a synaptosome sample was immunoprecipitated with a control rabbit IgG. IP was followed by immunoblotting (IB) using: (1) PSD95 (mouse) and
(2) GluA1 (rabbit) antibodies in B; and (1) GluA1 (rabbit) and (2) 16%, p ϭ 0.023 vs basal, n ϭ 6, unpaired Student's t test), demonstrating intact capacity for synaptic potentiation. However, no further increase in the number of potentiated synapses was observed with any tested treatment ( p Ͼ 0.05; Fig. 8A ). Interestingly, while basal GluA1 ϩ Nrx1␤ ϩ levels (in the absence of cLTP stimulation) were not significantly affected by any drug treatment either in AD or in control cases, a trend for increased basal potentiation state was observed in the presence of PDE5 inhibition (vardenafil) with GC activ in synaptosomes from control human cases (Fig. 8B) . These data demonstrate that FASS-LTP is a sensitive and efficient approach to screen for drugs acting directly on mechanisms underlying human LTP, allowing for simultaneous testing of multiple samples and treatment conditions. FASS-LTP identified PDE5 and PDE9, two enzymes expressed in human neurons (Kleiman et al., 2012; Teich et al., 2016) , as specific molecular targets for inhibition to rescue synaptic potentiation in human AD synapses. The data also indicate that PDE inhibition would be minimally effective to enhance potentiation in synapses that have intact cLTP, observed in control human cases. The lack of further cLTP enhancement in control human tissue resembles the limit on the maximum LTP capable of being induced by a series of bursts (LTP "ceiling"), and is consistent with the idea that that the LTP "ceiling" is relatively constant at the synapse level and may not be affected by pharmacological manipulations (Arai et al., 1994) . , 2006) . Forskolin was combined with BЈ, R, and C, which inhibit cAMP breakdown; whereas cinaciguat was combined with V, S, T, B, and BЈ to increase cGMP production while preventing cGMP hydrolysis. BЈ was combined with both forskolin and cinaciguat as this compound inhibits PDE2, an enzyme that hydrolyzes both cAMP and cGMP. Treatments are shown in identical order in both cLTP (B) and basal (C) conditions. Table 1 contains information on AD cases.
Discussion
Using FASS-LTP, we demonstrate that the increase in surface GluA1 and Nrx1␤ levels by cLTP in synaptosomes closely resembles synapse potentiation, the unitary event underlying LTP in intact circuitries. Indeed, we found that electrical stimulation in hippocampal slices also increases synaptosomal surface levels of GluA1 and Nrx1␤. Consistent with this finding, our data demonstrate that the cLTP response in synaptosomes mechanistically parallels the facilitation of synaptic transmission following electrically induced LTP in brain slices (e.g., dependence on CaMKIIand BDNF signaling). Further, using our sensitive flow cytometry approach to study plasticity directly at the synapse (Fig. 9 ), we demonstrate that LTP is impaired in synapses from animal models of neurodegeneration, but more importantly, in human AD brain. The application of FASS-LTP directly to human brain tissue represents an innovative strategy to efficiently identify plasticity-enhancing drugs that are effective in humans. Further, use of FASS-LTP to screen drugs before preclinical pharmacological target validation would speed translation from animal models to clinical trials, a major advance in the field. Our study incorporates multiple features in one design to study LTP in isolated synaptosomes. Several key features of our approach extend prior studies, which have demonstrated that synaptosome stimulation with glutamate, glycine, and/or KCl increases GluA1 and GluA2 levels in purified PSD fractions (Corera et al., 2009) , as well as the synthesis of proteins involved in synaptic plasticity (␣-CaMKII, Arc, Homer, and BDNF) (Bagni et al., 2000; Gharami and Das, 2014) . We have used a fluorescence-labeled antibody directed to the N-terminal domain of GluA1 to detect surface localized GluA1 extending previous methods using [ 3 H]-AMPA to detect AMPA receptors in isolated synaptosome membranes (Corera et al., 2009 ). In addition, we also demonstrate that glycine-KCl stimulation increases GluA1-PSD95 physical interaction in size-sorted synaptosomes. GluA1 clustering at the PSD likely reflects GluA1containing endosome insertion at the postsynaptic plasma membrane, as this is a main process regulating activity-dependent synaptic trafficking of AMPAR (Ehlers, 2000; Park et al., 2004 Park et al., , 2006 . The introduction of flow cytometry for synaptosome analysis (flow synaptometry) provides a means to efficiently detect changes in surface localized GluA1 and Nrx1␤, two key synaptic receptors for enduring LTP. The use of double label with GluA1 and Nrx1 ensures that we focus on synaptosomes with both presynaptic and postsynaptic elements. Our data indicate that a significant number of "integral synapses" can be detected by analyzing thousands of particles using flow synaptometry. Indeed, we have consistently found that up to ϳ25% of the size-gated synaptosomes increase surface GluA1 levels after cLTP stimulation, thus suggesting that a reliable fraction of particles (ϳ2500 of 10,000 acquired events) contains postsynaptic sealed spines with essential elements to support LTP (e.g., functional trafficking and cytoskeletal machinery), at least in the 1 to 2 h time window after stimulation.
In developing our FASS-LTP approach, while cLTP responses in neuronal cultures are evident with glycine stimulation alone (Lu et al., 2001; Park et al., 2006) , we reasoned that synaptosomal stimulation would benefit from additional KCl-dependent depolarization because synaptosomes lack firing-evoked neurotransmitter release. Therefore, we combined glycine pretreatment with mild KCl (37 mM) depolarization to emulate in vitro high activity states in synaptosomes. Our sequential glycine-KCl protocol robustly increases surface levels of GluA1 and Nrx1␤ over a time period of 15 min to at least 90 min, inducing a long-lasting response that is stronger than that observed with glycine-only or KCl-only stimulations (Fig. 4A) .
In contrast to current approaches to study activity-dependent responses by electrophysiological or biochemical methods in brain slices, neuronal cultures, and synaptosome preparations, FASS-LTP allows multiple conditions to be tested in parallel in a relatively short time, as the approach is based on simple procedures, requires only a small amount of tissue (milligrams), and is highly economical as drug testing is performed in small reaction volumes (200 -400 l).
In particular, we demonstrate that FASS-LTP can simultaneously test 30 -40 preparations from human brain tissue in ϳ5 h, using as little as 0.05-20 g of drugs in each experiment. Further, flow cytometry multiparameter analysis (Kling, 2015) in a single synaptosomal preparation may allow tracking cLTP responses in specific subsets of synapses (e.g., using transgenic mice expressing fluorescent reporters on neuron subtypes) (Lobo et al., 2006) . , 2006) . Forskolin was combined with BЈ, R, and C, which inhibit cAMP breakdown; whereas cinaciguat was combined with V, S, T, B, and BЈ to increase cGMP production while preventing cGMP hydrolysis. BЈ was combined with both forskolin and cinaciguat as this compound inhibits PDE2, an enzyme that hydrolyzes both cAMP and cGMP. Treatments are shown in identical order in both cLTP (A) and basal (B) conditions. Table 1 contains information of cases.
Despite a worldwide effort to identify drugs that alleviate memory deficits, such as occur in AD, no effective treatments currently exist despite Ͼ400 clinical trials (Cummings et al., 2014) . It has been suggested that the failure to translate animal model findings to humans may be overcome by target validation using a preclinical screening platform that is based on testing in adult human brain tissue (Dragunow, 2008) . Our data indicate that FASS-LTP is a highly translational approach, as it has revealed pharmaceutical agents that enhance LTP in human brain synaptosomes. Indeed, we have identified the cGMP pathway as a target for rescuing cLTP in AD-dysfunctional synapses. Our data show that PDE5 inhibition by vardenafil, an FDA-approved drug that prevents cGMP breakdown, increased GluA1 ϩ Nrx1␤ ϩ levels in synaptosomes treated with cinaciguat, a GCactivator in Phase IIb investigation (Clinical trial NCT01064037) that increases cGMP levels. Although vardenafil is currently used for treating vascular dysfunction and pulmonary hypertension, it crosses the blood-brain barrier (Reneerkens et al., 2012) , a key characteristic for consideration in the treatment of cognitive decline. Consistent with our data, vardenafil increases brain cGMP levels and improves memory in adult rats (Prickaerts et al., 2002; Reneerkens et al., 2012; Bollen et al., 2015) ; specifically in standard housed rats but not in rats housed in an enriched environment, suggesting a ceiling effect under optimal cognitive stimulation (Akkerman et al., 2014) . Indeed, studies in humans suggest that vardenafil may improve cognition in lowcognitive performers, but not in highlevel educated subjects (Reneerkens et al., 2013) . Surprisingly, the other PDE5 inhibitors that we tested (sildenafil and tadalafil) did not enhance the cLTP response. However, it is known that vardenafil is more potent than sildenafil for improving memory in rats (Prickaerts et al., 2002) , even though these two PDE5i have similar structures, suggesting that further drug optimization of PDE inhibitors could be achieved with chemical modifications. Further consistent with the idea that synaptic plasticity in the AD brain may be rescued by enhancing cGMP signaling, we also found that in the presence of cinaciguat (guanylyl cyclase activator), the PDE9 inhibitor Bay-73-6691 increased the cLTP response in AD synapses. Supporting this finding, Bay-73-6691 increases hippocampal cGMP levels, improves memory in Tg2576 mice, and restores LTP impaired by amyloid ␤ oligomers (Kroker et al., 2014) . The particular effect of vardenafil and Bay-73-6691 in AD synaptosomes is further supported by mRNA analysis showing that in AD cortical tissue the expression of PDE5 is significantly increased, and PDE9 expression shows a tendency to increase (Ugarte et al., 2015) , whereas the expression of PDE2 (Reyes-Irisarri et al., 2007) and PDE4 (Ugarte et al., 2015) is not altered, relative to age-matched controls. Although further research is needed to evaluate the efficacy of cGMP-related PDEi to improve cognitive in AD, our data provide a proof of concept for FASS-LTP as an efficient method for drug screening and preclinical target validation.
Although there are a number of challenges with using postmortem human brain tissue in research, with one of the most significant being the PMI, several reports indicate that basic biochemical reactions remain well preserved in the postmortem human brain. For instance, protein-protein interactions in human PSD fractions are relatively insensitive to variation in PMI (Ͻ15 h) or age (relatively constant from 70 to 90 years) (Hahn et al., 2009) . Moreover, glycine-dependent NMDAR activation (Hahn et al., 2006) and insulin signaling are relatively intact in low-PMI (Ͻ19 h) brain tissues, suggesting that glycine-dependent GluR1 and Nrx1␤ surface expression in synaptosomes is likely to be similarly resistant to some variables associated with a postmortem approach. Indeed, our data show that PMI does not have a significant effect on FASS-LTP when the delays are Ͻ9 h.
In conclusion, FASS-LTP provides new data directly on synapses and the status of LTP in human brain. Importantly, we provide support for a pharmacological strategy based on cGMP signaling enhancement to rescue LTP in the AD brain. Thus, our approach offers an exciting opportunity to scale-up LTP analyses to evaluate the potential of pharmaceutical and behavioral interventions to enhance plasticity in normal and diseased brains. (1) (2) (3) (4) Figure 9 . FASS-LTP overview. 1, Isolation of crude synaptosomal fraction (P2) containing intact synaptic units (sealed pre-and postsynaptic compartments) along with presynaptic terminals, free mitochondria, and cellular debris. 2, Glycine-KCl stimulation (cLTP). 3, Immunolabeling for surface (no permeabilization) GluA1 and Nrx1␤ to identify potentiated synapses. In accordance with previous reports, our data support a model where cLTP simultaneously orchestrates an upregulation of postsynaptic GluA1 levels while facilitating the expression of presynaptic Nrx1␤ at synaptosomal surface. In addition, reduced endocytosis (Dong et al., 2015) (dashed arrows) may also contribute to increase surface GluA1 and Nrx1␤ following cLTP. 4, Flow cytometry identifies potentiated synapses by size and GluA1 ϩ Nrx1␤ ϩ (extracellular) double labeling. Only tested on drug screening experiments (Fig. 7) .
